LXEO Lexeo Therapeutics, Inc.
company
SEC Filings & Insider Trading Activity 2026

CIK: 1907108
Health Care
Biological Products, (No Diagnostic Substances) 15 filings
Russell 2000

Latest Lexeo Therapeutics, Inc. (LXEO) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on March 30, 2026, a 10-Q quarterly report filed on November 5, 2025, an 8-K current report filed on April 30, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Lexeo Therapeutics, Inc. (LXEO) (SEC CIK 1907108), with AI-powered section-by-section summaries updated daily.

10-Q: 7
8-K: 5
10-K: 3

Latest 2026 SEC Filing Dates

10-K Annual Report
Mar 30, 2026
10-Q Quarterly Report
Nov 5, 2025
8-K Current Report
Apr 30, 2026

Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4

FormFiling DatePeriodAnalysisSEC
8-K
Apr 30, 2026
8-K
Mar 30, 2026
10-K
Mar 30, 2026Dec 31, 2025
8-K
Feb 5, 2026
8-K
Jan 27, 2026
8-K
Jan 12, 2026
10-Q
Nov 5, 2025Sep 30, 2025
10-Q
Aug 14, 2025Jun 30, 2025
10-Q
May 12, 2025Mar 31, 2025
10-K
Mar 24, 2025Dec 31, 2024
10-Q
Nov 13, 2024Sep 30, 2024
10-Q
Aug 12, 2024Jun 30, 2024
10-Q
May 9, 2024Mar 31, 2024
10-K
Mar 11, 2024Dec 31, 2023
10-Q
Dec 11, 2023Sep 30, 2023

Frequently Asked Questions

What are the latest LXEO SEC filings in 2026?

Lexeo Therapeutics, Inc. (LXEO) has filed a 10-K annual report on March 30, 2026, a 10-Q quarterly report on November 5, 2025, an 8-K current report on April 30, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did LXEO file its most recent 10-K annual report?

Lexeo Therapeutics, Inc. (LXEO) filed its most recent 10-K annual report on March 30, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view LXEO 10-Q quarterly reports?

Lexeo Therapeutics, Inc. (LXEO)'s most recent 10-Q quarterly report was filed on November 5, 2025. SignalX displays every LXEO 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has LXEO filed recently?

Lexeo Therapeutics, Inc. (LXEO)'s most recent 8-K was filed on April 30, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find LXEO insider trading activity (Form 4)?

SignalX aggregates every LXEO Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does LXEO file with the SEC?

Lexeo Therapeutics, Inc. (LXEO) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new LXEO filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Lexeo Therapeutics, Inc. (LXEO).

What is LXEO's SEC CIK number?

Lexeo Therapeutics, Inc. (LXEO)'s SEC CIK (Central Index Key) number is 1907108. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1907108 to look up all LXEO filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find LXEO return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Lexeo Therapeutics, Inc. (LXEO) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.

Stay on top of Lexeo Therapeutics, Inc. SEC filings

Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 15+ filings.